AVTOZMA® is Celltrion’s twelfth biosimilar to obtain marketing authorization in the European Union. Stay tuned to Big Molecule Watch for more regulatory updates on biosimilars.

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai ...

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company has been selected and will be included as a constituent of the Hang ...

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

Rheumatoid arthritis (RA) is a chronic autoimmune disease (one in which the immune system attacks healthy cells) that primarily affects your joints. It is a progressive condition that gets worse over ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new ...

The researchers also analyzed data from a clinical trial in which the anti-inflammatory drug tocilizumab was given to patients shortly after a heart attack. The analysis showed that the drug ...